Share This Article:

Exploration of the Relationship between Adipocytokines, Tradition Risk Markers, Nontraditional Risk Markers and Anthropometric Measurements in T2DM Patients

Abstract Full-Text HTML XML Download Download as PDF (Size:429KB) PP. 184-200
DOI: 10.4236/jbise.2015.83018    3,497 Downloads   3,867 Views   Citations


Obesity is commonly associated with type 2 diabetes and vascular disease. Changes in body composition in the obese state lead to a dysregulation of secretion of adipocyte-secreted hormones known as adipokines. The current study aimed to assess the relative physiological correlation of adipocytokines with immunity in urban Saudi patients. The serum adipocytokine (leptin, adiponectin, resistin, visfatin and apelin), metabolic parameters (insulin, fasting glucose, HbA1c % (Glycated Hemoglobin) immunological indices (IgG, IgA, IgM and IgE) and complement factors (C3, C4) in different metabolic disorders states such as obesity and T2DM (Type 2 Diabetes Mellitus) were determined. A total 100 adult male subjects were enrolled including 30 healthy that served as a control, 25 Glucophage treated T2DM, 22 overweight (Body Mass Index (BMI) ≥ 25 - 29.99) and 23 obese (BMI ≥ 30) patients. The current results showed that serum adipocytokines status has altered in obesity and treated T2DM compared to healthy individuals. In addition to HbA1c %, serum visfatin was also the prominent biomarker adipokine in treated T2DM while leptin was the highest in obese (BMI ≥ 30). These metabolic disorders did not affect serum levels of the assessed immunity indices. Current knowledge suggests that adipokines provide potential therapeutic targets against type 2 diabetes and vascular disease. This study provides a strong association between adipocytokine and IR (Insulin Resistance). With the increasing epidemic of obesity and T2DM in Saudi Arabia, these adipocytokine markers that integrate metabolic and inflammatory signals may play important roles in the treatment and prevention of obesity and diabetes as well as planning of therapeutic strategies and the early detection of diabetes.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Al-Sowayan, N. (2015) Exploration of the Relationship between Adipocytokines, Tradition Risk Markers, Nontraditional Risk Markers and Anthropometric Measurements in T2DM Patients. Journal of Biomedical Science and Engineering, 8, 184-200. doi: 10.4236/jbise.2015.83018.


[1] IDF (2011) Diabetes Atlas. 15th Edition, International Diabetes Federation (IDF).
[2] Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S. and Lazar, M.A. (2001) The Hormone Resistin Links Obesity to Diabetes. Nature, 409, 307-312.
[3] Goldstein, B.J. (2002) Insulin Resistance as the Core Defect in Type 2 Diabetes Mellitus. The American Journal of Cardiology, 90, 3G-10G.
[4] Lempiainen, P., Mykkanen, L., Pyorala, K., Laakso, M. and Kuusisto, J. (1999) Insulin Resistance Syndrome Predicts Coronary Heart Disease Events in Elderly Nondiabetic Men. Circulation, 100, 123-128.
[5] Mlinar, B., Marc, J., Janez, A. and Pfeifer, M. (2007) Molecular Mechanisms of Insulin Resistance and Associated Diseases. Clinica Chimica Acta, 375, 20-35.
[6] Ingelsson, E., Arnlov, J., Lind, L. and Sundstrom, J. (2006) Metabolic Syndrome and Risk for Heart Failure in Middle-Aged Men. Heart, 92, 1409-1413.
[7] Lakka, H.M., Laaksonen, D.E., Lakka, T.A., Niskanen, L.K., Kumpusalo, E., et al. (2002) The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-Aged Men. JAMA, 288, 2709-2716.
[8] Kahn, S.E., Hull, R.L. and Utzschneider, K.M. (2006) Mechanisms Linking Obesity to Insulin Resistance and Type 2 Diabetes. Nature, 444, 840-846.
[9] Weiss, R., Dziura, J., Burgert, T.S., et al. (2004) Obesity and the Metabolic Syndrome in Children and Adolescents. The New England Journal of Medicine, 350, 2362-2374.
[10] Ouchi, N., Kihara, S., Funahashi, T., Matsuzawa, Y. and Walsh, K. (2003) Obesity, Adiponectin and Vascular Inflammatory Disease. Current Opinion in Lipidology, 14, 561-566.
[11] Koerner, A., Kratzsch, J. and Kiess, W. (2005) Adipocytokines: Leptin—The Classical, Resistin—The Controversical, Adiponectin—The Promising, and More to Come. Best Practice & Research Clinical Endocrinology & Metabolism, 19, 525-546.
[12] Tilg, H. and Moschen, A.R. (2006) Adipocytokines: Mediators Linking Adipose Tissue, Inflammation and Immunity. Nature Reviews Immunology, 6, 772-783.
[13] Matsuzawa, Y. (2005) Adipocytokines and Metabolic Syndrome. Seminars in Vascular Medicine, 5, 34-39.
[14] Rabin, K.R., Kamari, Y., Avni, I., Grossman, E. and Sharabi, Y. (2005) Adiponectin: Linking the Metabolic Syndrome to Its Cardiovascular Consequences. Expert Review of Cardiovascular Therapy, 3, 465-471.
[15] Guzik, T.J., Korbut, R. and Adamek-Guzik, T. (2003) Nitric Oxide and Superoxide in Inflammation and Immune Regulation. Journal of Physiology and Pharmacology, 54, 469-487.
[16] Klaus, S. (2004) Adipose Tissue as a Regulator of Energy Balance. Current Drug Targets, 5, 241-250.
[17] Matsuzawa, Y. (2010) Adiponectin: A Key Player in Obesity Relate Disorders. Current Pharmaceutical Design, 16, 1896-1901.
[18] Falcao-Pires, I., Castro-Chaves, P., Miranda-Silva, D., Lourenco, A.P. and Leite-Moreira, A.F. (2012) Physiological, Pathological and Potential Therapeutic Roles of Adipokines. Drug Discovery Today, 17, 880-889.
[19] Pelleymounter, M.A., Cullen, M.J., Baker, M.B., Hecht, R., Winters, D., Boone, T., et al. (1995) Effects of the Obese Gene Product on Body Weight Regulation in ob/ob Mice. Science, 269, 540-543.
[20] Lee, G.H., Proenca, R., Montez, J.M., Carroll, K.M., Darvishzadeh, J.G., Lee, J.I., et al. (1996) Abnormal Splicing of the Leptin Receptor in Diabetic Mice. Nature, 379, 632-635.
[21] Saladin, R., De Vos, P., Guerre-Millo, M., Leturque, A., Girard, J., Staels, B., et al. (1995) Transient Increase in Obese Gene Expression after Food Intake or Insulin Administration. Nature, 377, 527-529.
[22] Geffroy, S., De Vos, P., Staels, B., Duban, B., Auwerx, J. and de Martinville, B. (1995) Localization of the Human OB Gene (OBS) to Chromosome 7q32 by Fluorescence in Situ Hybridization. Genomics, 28, 603-604.
[23] Brzozowski, T., Konturek, P.C., Konturek, S.J., Brzozowska, I. and Pawlik, T. (2005) Role of Prostaglandins in Gastroprotection and Gastric Adaptation. Journal of Physiology and Pharmacology, 56, 33-55.
[24] Nawrot-Porabka, K., Jaworek, J., Leja-Szpak, A., Palonek, M., Szklarczyk, J., Konturek, S.J., et al. (2004) Leptin Is Able to Stimulate Pancreatic Enzyme Secretion via Activation of Duodeno-Pancreatic Reflex and CCK Release. Journal of Physiology and Pharmacology, 55, 47-57.
[25] Konturek, P.C., Brzozowski, T., Burnat, G., Kwiecien, S., Pawlik, T., Hahn, E.G., et al. (2004) Role of Brain-Gut Axis in Healing of Gastric Ulcers. Journal of Physiology and Pharmacology, 55, 179-192.
[26] Konturek, S.J., Konturek, J.W., Pawlik, T. and Brzozowski, T. (2004) Brain-Gut Axis and Its Role in the Control of Food Intake. Journal of Physiology and Pharmacology, 55, 137-154.
[27] Konturek, S.J., Pepera, J., Zabielski, K., Konturek, P.C., Pawlik, T., Szlachcic, A., et al. (2003) Brain-Gut Axis in Pancreatic Secretion and Appetite Control. Journal of Physiology and Pharmacology, 54, 293-317.
[28] Farooqi, I.S., Matarese, G., Lord, G.M., Keogh, J.M., Lawrence, E., Agwu, C., et al. (2002) Beneficial Effects of Leptin on Obesity, T Cell Hyporesponsiveness, and Neuroendocrine/Metabolic Dysfunction of Human Congenital Leptin Deficiency. Journal of Clinical Investigation, 110, 1093-1103.
[29] Montague, C.T., Farooqi, I.S., Whitehead, J.P., Soos, M.A., Rau, H., Wareham, N.J., et al. (1997) Congenital Leptin Deficiency Is Associated with Severe Early-Onset Obesity in Humans. Nature, 387, 903-908.
[30] Zoladz, J.A., Konturek, S.J., Duda, K., Majerczak, J., Sliwowski, Z., Grandys, M., et al. (2005) Effect of Moderate Incremental Exercise, Performed in Fed and Fasted State on Cardio-Respiratory Variables and Leptin and Ghrelin Concentrations in Young Healthy Men. Journal of Physiology and Pharmacology, 56, 63-85.
[31] Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R., et al. (1996) Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans. New England Journal of Medicine, 334, 292-295.
[32] Kim, S., Whelan, J., Claycombe, K., Reath, D.B. and Moustaid-Moussa, N. (2002) Angiotensin II Increases Leptin Secretion by 3T3-L1 and Human Adipocytes via a Prostaglandin-Independent Mechanism. Journal of Nutrition, 132, 1135-1140.
[33] Ran, J., Hirano, T., Fukui, T., Kageyama, H., Okada, K. and Adachi, M. (2006) Angiotensin II Infusion Decreases Plasma Adiponectin Level via Its Type 1 Receptor in Rats: An Implication for Hypertension-Related Insulin Resistance. Metabolism, 55, 478-488.
[34] Kaminski, T., Smolinska, N., Gajewska, A., Siawrys, G., Okrasa, S., Kochman, K., et al. (2006) Leptin and Long Form of Leptin Receptor Genes Expression in the Hypothalamus and Pituitary during the Luteal Phase and Early Pregnancy in Pigs. Journal of Physiology and Pharmacology, 57, 95-108.
[35] Beltowski, J., Marciniak, A. and Wojcicka, G. (2004) Leptin Decreases Renal Medullary Na(+), K(+)-ATPase Activity through Phosphatidylinositol 3-Kinase Dependent Mechanism. Journal of Physiology and Pharmacology, 57, 391-407.
[36] Jaworek, J., Bonior, J., Konturek, S.J., Bilski, J., Szlachcic, A. and Pawlik, W.W. (2003) Role of Leptin in the Control of Postprandial Pancreatic Enzyme Secretion. Journal of Physiology and Pharmacology, 57, 591-602.
[37] Stallmeyer, B., Pfeilschifter, J. and Frank, S. (2001) Systemically and Topically Supplemented Leptin Fails to Reconstitute a Normal Angiogenic Response during Skin Repair in Diabetic ob/ob mice. Diabetologia, 44, 471-479.
[38] Kougias, P., Chai, H., Lin, P.H., Yao, Q., Lumsden, A.B. and Chen, C. (2005) Effects of Adipocyte-Derived Cytokines on Endothelial Functions: Implication of Vascular Disease. Journal of Surgical Research, 126, 121-129.
[39] Schwartz, M.W., Woods, S.C., Porte Jr., D., Seeley, R.J. and Baskin, D.G. (2000) Central Nervous System Control of Food Intake. Nature, 404, 661-671.
[40] Friedman, J.M. and Halaas, J.L. (1998) Leptin and the Regulation of Body Weight in Mammals. Nature, 395, 763-770.
[41] Kaur, T. and Zhang, Z.F. (2005) Obesity, Breast Cancer and the Role of Adipocytokines. Asian Pacific Journal of Cancer Prevention, 6, 547-552.
[42] Kubota, N., Terauchi, Y., Yamauchi, T., Kubota, T., Moroi, M., Matsui, J., et al. (2002) Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation. Journal of Biological Chemistry, 277, 25863-25866.
[43] Xu, A., Yin, S., Wong, L., Chan, K.W. and Lam, K.S. (2004) Adiponectin Ameliorates Dyslipidemia Induced by the Human Immunodeficiency Virus Protease Inhibitor Ritonavir in Mice. Endocrinology, 145, 487-494.
[44] Yoon, M.J., Lee, G.Y., Chung, J.J., Ahn, Y.H., Hong, S.H. and Kim, J.B. (2006) Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential Activation of AMP-Activated Protein Kinase, p38 Mitogen-Activated Protein Kinase, and Peroxisome Proliferator-Activated Receptor Alpha. Diabetes, 55, 2562-2570.
[45] Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., et al. (2003) Cloning of Adiponectin Receptors That Mediate Antidiabetic Metabolic Effects. Nature, 423, 762-769.
[46] Qi, Y., Takahashi, N., Hileman, S.M., Patel, H.R., Berg, A.H., Pajvani, U.B., Scherer, P.E. and Ahima, R.S. (2004) Adiponectin Acts in the Brain to Decrease Body Weight. Nature Medicine, 10, 524-529.
[47] Neumeier, M., Weigert, J., Schaffler, A., Wehrwein, G., Müller-Ladner, U., Scholmerich, J., et al. (2006) Different Effects of Adiponectin Isoforms in Human Monocytic Cells. Journal of Leukocyte Biology, 79, 803-808.
[48] Wasim, H., Al-Daghri, N.M., Chetty, R., McTernan, P.G., Barnett, A.H. and Kumar, S. (2006) Relationship of Serum Adiponectin and Resistin to Glucose Intolerance and Fat Topography in South-Asians. Cardiovascular Diabetology, 5, 10.
[49] Fain, J.N. (2006) Release of Interleukins and Other Inflammatory Cytokines by Human Adipose Tissue Is Enhanced in Obesity and Primarily Due to the Nonfat Cells. Vitamins & Hormones, 74, 443-477.
[50] Bastard, J.P., Maachi, M., Lagathu, C., Kim, M.J., Caron, M., Vidal, H., et al. (2006) Recent Advances in the Relationship between Obesity, Inflammation, and Insulin Resistance. European Cytokine Network, 17, 4-12.
[51] Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., et al. (2005) Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin. Science, 307, 426-430.
[52] Beltowski, J. (2006) Apelin and Visfatin: Unique “Beneficial” Adipokines Upregulated in Obesity? Medical Science Monitor, 12, RA112-RA119.
[53] Haider, D.G., Schaller, G., Kapiotis, S., Maier, C., Luger, A. and Wolzt, M. (2006) The Release of the Adipocytokine Visfatin Is Regulated by Glucose and Insulin. Diabetologia, 49, 1909-1914.
[54] Revollo, J.R., Korner, A., Mills, K.F., Satoh, A., Wang, T., Garten, A., et al. (2007) Nampt/PBEF/Visfatin Regulates Insulin Secretion in Beta Cells as a Systemic NAD Biosynthetic Enzyme. Cell Metabolism, 6, 363-375.
[55] Brown, J.E., Onyango, D.J., Ramanjaneya, M., Conner, A.C., Patel, S.T., Dunmore, S.J., et al. (2010) Visfatin Regulates Insulin Secretion, Insulin Receptor Signalling and mRNA Expression of Diabetes-Related Genes in Mouse Pancreatic Beta-Cells. Journal of Molecular Endocrinology, 44, 171-178.
[56] Lan, J., Chen, X., Wang, S., Wanga, S., Zhang, X., Wu, K., et al. (2011) The Relationship between Visfatin and HOMA-IR in Hypertensive Patients, and the Effect of Antihypertensive Drugs on Visfatin and HOMA-IR in Hypertensive Patients with Insulin Resistance. Diabetes Research and Clinical Practice, 94, 71-76.
[57] Straburzynska-Lupa, A., Nowak, A., Pilaczynska-Szczesniak, L., Straburzyńska-Migaj, E., Romanowski, W., Karolkiewicz, J., et al. (2010) Visfatin, Resistin, hsCRP and Insulin Resistance in Relation to Abdominal Obesity in Women with Rheumatoid Arthritis. Clinical and Experimental Rheumatology, 28, 19-24.
[58] Tatemoto, K., Takayama, K., Zou, M.X., Kumaki, I., Zhang, W., et al. (2001) The Novel Peptide Apelin Lowers Blood Pressure via a Nitric Oxide-Dependent Mechanism. Regulatory Peptides, 99, 87-92.
[59] Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigne, C., et al. (2005) Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity. Endocrinology, 146, 1764-1771.
[60] El Messari, S., Iturrioz, X., Fassot, C., De Mota, N., Roesch, D., et al. (2004) Functional Dissociation of Apelin Receptor Signaling and Endocytosis: Implications for the Effects of Apelin on Arterial Blood Pressure. Journal of Neurochemistry, 90, 1290-1301.
[61] Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., et al. (1998) Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor. Biochemical and Biophysical Research Communications, 251, 471-476.
[62] Castan-Laurell, I., Dray, C., Knauf, C., Kunduzova, O. and Valet, P. (2012) Apelin, a Promising Target for Type 2 Diabetes Treatment? Trends in Endocrinology and Metabolism, 23, 234-241.
[63] Attané, C., Foussal, C., Le Gonidec, S., Benani, A., Daviaud, D., Wanecq, E., et al. (2012) Apelin Treatment Increases Complete Fatty Acid Oxidation, Mitochondrial Oxidative Capacity, and Biogenesis in Muscle of Insulin-Resistant Mice. Diabetes, 61, 310-320.
[64] Yue, P., Jin, H., Xu, S., Aillaud, M., Deng, A.C., et al. (2011) Apelin Decreases Lipolysis via Gq, Gi, and AMPK-Dependent Mechanisms. Endocrinology, 152, 59-68.
[65] Attané, C., Daviaud, D., Dray, C., Dusaulcy, R., Masseboeuf, M., Prévot, D., et al. (2011) Apelin Stimulates Glucose Uptake but Not Lipolysis in Human Adipose Tissue ex Vivo. Journal of Molecular Endocrinology, 46, 21-28.
[66] Guo, L., Li, Q., Wang, W., Yu, P., Pan, H., Li, P., et al. (2009) Apelin Inhibits Insulin Secretion in Pancreatic Beta-Cells by Activation of PI3-Kinase-Phosphodiesterase 3B. Endocrine Research, 34, 142-154.
[67] Soriguer, F., Garrido-Sanchez, L., Garcia-Serrano, S., Garcia-Almeida, J.M., Garcia-Arnes, J., et al. (2009) Apelin Levels Are Increased in Morbidly Obese Subjects with Type 2 Diabetes Mellitus. Obesity Surgery, 19, 1574-1580.
[68] Dray, C., Debard, C., Jager, J., Disse, E., Daviaud, D., Martin, P., et al. (2010) Apelin and APJ Regulation in Adipose Tissue and Skeletal Muscle of Type 2 Diabetic Mice and Humans. American Journal of Physiology: Endocrinology and Metabolism, 298, E1161-E1169.
[69] Erdem, G., Dogru, T., Tasci, I., Sonmez, A. and Tapan, S. (2008) Low Plasma Apelin Levels in Newly Diagnosed Type 2 Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes, 116, 289-292.
[70] Zhang, Y., Shen, C., Li, X., Ren, G., Fan, X., Ren, F., et al. (2009) Low Plasma Apelin in Newly Diagnosed Type 2 Diabetes in Chinese People. Diabetes Care, 32, e150.
[71] Meral, C., Tascilar, E., Karademir, F., Tanju, I.A., Cekmez, F., Metin, O., et al. (2010) Elevated Plasma Levels of Apelin in Children with Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 23, 497-502.
[72] Telejko, B., Kuzmicki, M., Wawrusiewicz-Kurylonek, N., Szamatowicz, J., Nikolajuk, A., Zonenberg, A., et al. (2010) Plasma Apelin Levels and Apelin/APJ mRNA Expression in Patients with Gestational Diabetes Mellitus. Diabetes Research and Clinical Practice, 87, 176-183.
[73] Kouyama, K., Miyake, K., Zenibayashi, M., Hirota, Y., Teranishi, T., Tamori, Y., et al. (2007) Association of Serum MCP-1 Concentration and MCP-1 Polymorphism with Insulin Resistance in Japanese Individuals with Obese Type 2 Diabetes. Kobe Journal of Medical Sciences, 53, 345-354.
[74] Suzuki, T., Imai, J., Yamada, T., Ishigaki, Y., Kaneko, K., Uno, K., et al. (2011) Interleukin-6 Enhances Glucose-Stimulated Insulin Secretion from Pancreatic Beta-Cells: Potential Involvement of the PLC-IP3-Dependent Pathway. Diabetes, 60, 537-547.
[75] Besedovsky, H.O. and Del Rey, A. (2010) Interleukin-1 Resets Glucose Homeostasis at Central and Peripheral Levels: Relevance for Immunoregulation. Neuroimmunomodulation, 17, 139-141.
[76] Enomoto, T., Ohashi, K., Shibata, R., Higuchi, A., Maruyama, S., Izumiya, Y., et al. (2011) Adipolin/C1qdc2/CTRP12 Protein Functions as an Adipokine That Improves Glucose Metabolism. Journal of Biological Chemistry, 286, 34552-34558.
[77] Choi, J.H., Rhee, E.J., Kim, K.H., Woo, H.Y., Lee, W.Y. and Sung, K.C. (2011) Plasma Omentin-1 Levels Are Reduced in Non-Obese Women with Normal Glucose Tolerance and Polycystic Ovary Syndrome. European Journal of Endocrinology, 165, 789-796.
[78] Lamers, D., Famulla, S., Wronkowitz, N., Hartwig, S., Lehr, S., Ouwens, D.M., et al. (2011) Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome. Diabetes, 60, 1917-1925.
[79] El-Hazmi, M.A.F., Warsy, A.S., Al-Swailem, A.R., Al-Swailem, A.M. and Sulaimani, R. (1998) Diabetes Mellitus as a Health Problem in Saudi Arabia. Eastern Mediterranean Health Journal, 4, 58-67.
[80] Al-Nozha, M.M., Al-Maatouq, M.A., Al-Mazrou, Y.Y., Al-Harthi, S.S., Arafah, M.R., Khalil, M.Z., Khan, N.B., Al-Khadra, A., Al-Marzouki, K., Nouh, M.S., Abdullah, M., Attas, O., Al-Shahid, M.S. and Al-Mobeireek, A. (2009) Diabetes Mellitus in Saudi Arabia. Saudi Medical Journal, 25, 1603-1610. King Fahd University of Petroleum & Minerals.
[81] Gokalp, D., Bahceci, M., Ozmen, S., Arikan, S., Tuzcu, A. and Danis, R. (2008) Adipocyte Volumes and Levels of Adipokines in Diabetes and Obesity. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2, 253-258.
[82] Gualillo, O., González-Juanatey, J.R. and Lago, F. (2007) The Emerging Role of Adipokines as Mediators of Cardiovascular Function: Physiologic and Clinical Perspectives. Trends in Cardiovascular Medicine, 17, 275-283.
[83] Esteghamati, A., Alamdari, A., Zandieh, A., Elahi, S., Khalilzadeh, O., Nakhjavani, M. and Meysamie, A. (2011) Serum Visfatin Is Associated with Type 2 Diabetes Melitus Independent of Insulin Resistance and Obesity. Diabetes Research and Clinical Practice, 91, 154-158.
[84] Alghasham, A.A. and Barakat, Y.A. (2008) Serum Visfatin and Its Relation to Insulin Resistance and Inflammation in Type 2 Diabetic Patients with and without Macroangiopathy. Saudi Medical Journal, 29, 185-192.
[85] Chang, Y.H., Chang, D.M., Lin, K.C., Shin, S.J. and Lee, Y.J. (2011) Visfatin in Overweight/Obesity, Type 2 Diabetes Mellitus, Insulin Resistance, Metabolic Syndrome and Cardiovascular Diseases: A Meta-Analysis and Systemic Review. Diabetes/Metabolism Research and Reviews, 27, 515-527.
[86] El-Mesallamy, H.O., Kassem, D.H., El-Demerdash, E. and Amin, A.I. (2011) Vaspin and Visfatin/Nampt Are Interesting Interrelated Adipokines Playing a Role in the Pathogenesis of Type 2 Diabetes Mellitus. Metabolism, 60, 63-70.
[87] Sandeep, S., Velmurugan, K., Deepa, R. and Mohan, V. (2007) Serum Visfatin in Relation to Visceral Fat, Obesity, and Type 2 Diabetes Mellitus in Asian Indians. Metabolism, 56, 565-570.
[88] Shaker, O., El-Shehaby, A., Zakaria, A., Mostafa, N., Talaat, S., Katsiki, N. and Mikhailidis, D.P. (2011) Plasma Visfatin and Retinol Binding Protein-4 Levels in Patients with Type 2 Diabetes Mellitus and Their Relationship to Adiposity and Fatty Liver. Clinical Biochemistry, 44, 1457-1463.
[89] Meshkani, R. and Adeli, K. (2009) Hepatic Insulin Resistance, Metabolic Syndrome and Cardiovascular Disease. Clinical Biochemistry, 42, 1331-1346.
[90] Zhu, J., Schott, M., Liu, R., Liu, C., Shen, B., Wang, Q., Mao, X., Xu, K., Wu, X., Schinner, S., Papewalis, C., Scherbaum, W.A. and Liu, C. (2008) Intensive Glycemic Control Lowers Plasma Visfatin Levels in Patients with Type 2 Diabetes. Hormone and Metabolic Research, 40, 801-805.
[91] Bloomgarden, Z.T. (2002) New Insights in Obesity. Diabetes Care, 25, 789-795.
[92] Chen, M.P., Chung, F.M., Chang, D.M., Tsai, J.C.R., Huang, H.F., Shin, S.J., et al. (2006) Elevated Plasma Level of Visfatin/Pre-B Cell Colony-Enhancing Factor in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology & Metabolism, 91, 295-299.
[93] Miao-Pei, C., et al. (2006) Elevated Plasma Level of Visfatin/Pre-B Cell Colony Enhancing Factor in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology & Metabolism, 91, 295-299.
[94] Kaminska, A., Kopczyńska, E., Bronisz, A., Zmudzińska, M., Bieliński, M., Borkowska, A., et al. (2010) An Evaluation of Visfatin Levels in Obese Subjects. Endokrynologia Polska, 61, 169-173.
[95] Tasci, I., Erdem, G., Ozgur, G., Tapan, S., Dogru, T., Genc, H., et al. (2009) LDL-Cholesterol Lowering Increases Plasma Apelin in Isolated Hypercholesterolemia. Atherosclerosis, 204, 222-228.
[96] Li, L., Yang, G., Li, Q., Tang, Y., Yang, M., Yang, H., et al. (2006) Changes and Relations of Circulating Visfatin, Apelin, and Resistin Levels in Normal, Impaired Glucose Tolerance, and Type 2 Diabetic Subjects. Experimental and Clinical Endocrinology & Diabetes, 114, 544-548.
[97] Dray, C., Knauf, C., Daviaud, D., Waget, A., Boucher, J., et al. (2008) Apelin Stimulates Glucose Utilization in Normal and Obese Insulin-Resistant Mice. Cell Metabolism, 8, 437-445.
[98] Horiuchi, Y., Fujii, T., Kamimura, Y. and Kawashima, K. (2003) The Endogenous, Immunologically Active Peptide Apelin Inhibits Lymphocytic Cholinergic Activity during Immunological Responses. Journal of Neuroimmunology, 144, 46-52.
[99] Ranjana, S., Fisch, G., Teague, B., Tamborlane, W.V., Banyas, B., Allen, K., et al. (2002) Prevalence of Impaired Glucose Tolerance among Children and Adolescents with Marked Obesity. New England Journal of Medicine, 346, 802-810.
[100] Lu, H.L., Wang, H.W., Wen, Y., Zhang, M.X. and Lin, H.H. (2006) Roles of Adipocyte Derived Hormone Adiponectin and Resistin in Insulin Resistance of Type 2 Diabetes. World Journal of Gastroenterology, 12, 1747-1751.
[101] Mojiminiyi, O.A. and Abdella, N.A. (2007) Associations of Resistin with Inflammation and Insulin Resistance in Patients with Type 2 Diabetes Mellitus. Scandinavian Journal of Clinical & Laboratory Investigation, 67, 215-225.
[102] Kusminski, C.M., McTernan, P.G. and Kumar, S. (2005) Role of Resistin in Obesity, Insulin Resistance and Type II Diabetes. Clinical Science, 109, 243-256.
[103] Ouchi, N., Parker, J.L., Lugus, J.J. and Walsh, K. (2011) Adipokines in Inflammation and Metabolic Disease. Nature Reviews Immunology, 11, 85-97.
[104] Sahu, A. (2011) Intracellular Leptin-Signaling Pathways in Hypothalamic Neurons: The Emerging Role of Phosphatidylinositol-3 Kinase-Phosphodesterase-3 B-Camp Pathway. Neuroendocrinology, 93, 201-210.
[105] Mataresse, G., La Cava, A., Sanna, V., Howard, J.K., Lord, G.M., Carravetta, C., Fontana, S., Lechler, R.I., Bloom, S.R. and De Placido, G. (2000) Increased Leptin Levels in Serum and Peritoneal Fluid of Patients with Pelvic Endometriosis. Journal of Clinical Endocrinology & Metabolism, 85, 2483-2487.
[106] Matarese, G., Sanna, V., Lechler, R.I., Sarvetnick, N., Fontana, S., Zappacosta, S., et al. (2002) Leptin Accelerates Autoimmune Diabetes in Female NOD Mice. Diabetes, 51, 1356-1361.
[107] Reilly, M.P., Iqbal, N., Schutta, M., Wolfe, M.L., Scally, M., Localio, A.R., Rader, D.J. and Kimmel, S.E. (2004) Plasma Leptin Levels Are Associated with Coronary Atherosclerosis in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism, 89, 3872-3878.
[108] Kamińska, A., Kopczyńska, E., Bronisz, A., Zmudzińska, M., Bieliński, M., Borkows, A., et al. (2010) An Evaluation of Visfatin Levels in Obese Subjects. Endokrynologia Polska, 61, 169-173.
[109] Wannamethee, S.G., Tchernova, J., Whincup, P., Lowe, G.D., Kelly, A., Rumley, A., Wallace, A.M. and Sattar, N. (2007) Plasma Leptin: Associations with Metabolic, Inflammatory and Haemostatic Risk Factors for Cardiovascular Disease. Atherosclerosis, 191, 418-426.
[110] Stefanovic, A., Kotur-Stevuljevic, J., Spasic, S., Bogavac-Stanojevic, N. and Bujisic, N. (2008) The Influence of Obesity on the Oxidative Stress Status and the Concen-tration of Leptin in Type 2 Diabetes Mellitus Patients. Diabetes Research and Clinical Practice, 79, 156-163.
[111] Abdella, N.A., Mojiminiyi, O.A., Moussa, M.A., Zaki, M., Al Mohammedi, H., Al Ozairi, E.S. and Al Jebely, S. (2005) Plasma Leptin Concentration in Patients with Type 2 Diabetes: Relationship to Cardiovascular Disease Risk Factors and Insulin Resistance. Diabetic Medicine, 22, 278-285.
[112] Asakawa, H., Tokunaga, K. and Kawakami, F. (2001) Relationship of Leptin Level with Metabolic Disorders and Hypertension in Japanese Type 2 Diabetes Mellitus Patients. Journal of Diabetes and its Complications, 15, 57-62.
[113] Thorand, B., Zierer, A., Baumert, J., Meisinger, C., Herder, C. and Koenig, W. (2010) Associations between Leptin and the Leptin/Adiponectin Ratio and Incident Type 2 Diabetes in Middle-Aged Men and Women: Results from the MONICA/KORA Augsburg Study 1984-2002. Diabetic Medicine, 27, 1004-1011.
[114] Maenhaut, N. and van de Voorde, J. (2011) Regulation of Vascular Tone by Adipocytes. BMC Medicine, 16, 9-25.
[115] Snehalatha, C., Mukesh, B., Simon, M., Viswanathan, V., Haffner, S.M. and Ramachandran, A. (2003) Plasma Adiponectin Is an Independent Predictor of Type 2 Diabetes in Asian Indians. Diabetes Care, 26, 3226-3229.
[116] Li, S., Shin, H.J., Ding, E.L. and van Dam, R.M. (2009) Adiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis. The Journal of the American Medical Association, 302, 179-188.
[117] Lautamaki, R., Ronnemaa, T., Huupponen, R., Lehtimaki, T., Iozzo, P., Airaksinen, K.E., Knuuti, J. and Nuutila, P. (2007) Low Serum Adiponectin Is Associated with High Circulating Oxidized Low-Density Lipoprotein in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. Metabolism, 56, 881-886.
[118] Matsuzawa, Y., Funahashi, T. and Nakamura, T. (1999) Molecular Mechanism of Metabolic Syndrome X: Contribution of Adipocytokines Adipocyte-Derived Bioactive Substances. Annals of the New York Academy of Sciences, 892, 146-154.
[119] Kern, P.A., Di Gregorio, G.B., Lu, T., Rassouli, N. and Ranganathan, G. (2003) Adiponectin Expression from Human Adipose Tissue: Relation to Obesity, Insulin Resistance, and Tumor Necrosis Factor-α Expression. Diabetes, 52, 1779-1785.
[120] Okamoto, Y., Kihara, S., Ouchi, N., Nishida, M., Arita, Y., Kumada, M., Ohashi, K., Sakai, N., Shimomura, I., Kobayashi, H., Terasaka, N., Inaba, T., Funahashi, T. and Matsuzawa, Y. (2002) Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice. Circulation, 106, 2767-2770.
[121] Spergel, J.M., Mizoguchi, E., Oettgen, H., Bhan, A.K. and Geha, R.S. (1999) Roles of TH1 and TH2 Cytokines in a Murine Model of Allergic Dermatitis. Journal of Clinical Investigation, 103, 1103-1111.
[122] Dubucquoi, S., Desreumaux, P., Janin, A., Klein, O., Goldman, M., Tavernir, J., Capron, A. and Capron, M. (1994) Interleukin 5 Synthesis by Eosinophils Association with Granules and Immunoglobulin Dependent Secretion. Journal of Experimental Medicine, 179, 703-708.
[123] Matsuzawa, Y., Funashi, T., Kihara, S. and Shimomura, I. (2004) Adiponectin and Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 29-33.
[124] Trujillo, M.E. and Scherer, P.E. (2005) Adiponectin Journey from an Adipocyte Secretory Protein to Biomarker of the Metabolic Syndrome. Journal of Internal Medicine, 257, 167-175.
[125] Halleux, C.N.M., Takahashi, M., Delporte, M.L., Detryc, R., Funahashi, T., Matsuzawa, Y. and Brichard, S.M. (2001) Secretion of Adiponectin and Regulation of apM1 Gene Expression in Human Visceral Adipose Tissue. Biochemical and Biophysical Research Communications, 288, 1102-1107.
[126] Nagaev, I. and Smith, U. (2001) Insulin Resistance and Type 2 Diabetes Are Not Related to Resistin Expression in Human Fat Cells or Skeletal Muscle. Biochemical and Biophysical Research Communications, 285, 561-564.
[127] Habib, S.S. (2012) Serum Resistin Levels in Patients with Type 2 Diabetes Mellitus and Its Relationship with Body Composition. Saudi Medical Journal, 33, 495-499.
[128] Gharibeh, M.Y., Al Tawallbeh, G.M., Abboud, M.M., Radaideh, A., Alhader, A.A. and Khabour, O.F. (2010) Correlation of Plasma Resistin with Obesity and Insulin Resistance in Type 2 Diabetic Patients. Diabetes & Metabolism, 6, 443-449.
[129] Sommer, G., Garten, A., Petzold, S., Beck-Sickinger, A.G., Bluher, M., Stumvoll, M., et al. (2008) Visfatin/PBEF/Nampt: Structure, Regulation and Potential Function of a Novel Adipokine. Clinical Science, 115, 13-23.
[130] Rego-Filho, E.A., Mello, S.F., Omuro, A.M. and Loli, J.O. (2003) Simultaneous Onset of Steroid-Sensitive Nephrotic Syndrome and Type 1 Diabetes. Jornal de Pediatria, 79, 557-560.
[131] Mantzoros, C., Petridou, E., Dessypris, N., Chavelas, C., Dalamaga, M., Alexe, D.M., et al. (2004) Adiponectin and Breast Cancer Risk. Journal of Clinical Endocrinology & Metabolism, 89, 1102-1107.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.